UMIN-CTR Clinical Trial

Recruitment status Completed
Unique ID issued by UMIN UMIN000001529
Receipt No. R000001846
Official scientific title of the study Phase II trial of irinotecan plus cisplatin for pretreated patients with Ewing sarcoma and PNET
Date of disclosure of the study information 2008/12/01
Last modified on 2018/12/13 (Ver. 6)

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information
Official scientific title of the study Phase II trial of irinotecan plus cisplatin for pretreated patients with Ewing sarcoma and PNET
Title of the study (Brief title) EFT-CPT-CDDP
Region
Japan

Condition
Condition pretreated Ewing sarcoma or PNET
Classification by specialty
Hematology and clinical oncology
Classification by malignancy Malignancy
Genomic information NO

Objectives
Narrative objectives1 Efficacy
Basic objectives2 Safety
Basic objectives -Others
Trial characteristics_1
Trial characteristics_2
Developmental phase

Assessment
Primary outcomes Response rate
Key secondary outcomes

Base
Study type Interventional

Study design
Basic design Single arm
Randomization Non-randomized
Randomization unit
Blinding Open -no one is blinded
Control Uncontrolled
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment

Intervention
No. of arms 1
Purpose of intervention Treatment
Type of intervention
Medicine
Interventions/Control_1 chemotherapy
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10

Eligibility
Age-lower limit
18 years-old <=
Age-upper limit

Not applicable
Gender Male and Female
Key inclusion criteria 1)Ewing sarcoma or PNET
2)Advanced, metastatic or recurrent case
3)Prior treated with anthracycline agents and ifomaide
4)At least one target lesion
Key exclusion criteria 1)Patient who have no indication for chemotherapy
Target sample size 32

Research contact person
Name of lead principal investigator Akira Kawai
Organization National cancer center hospital
Division name Orthopedic surgery
Address 5-1-1 Tsukiji, Chuo-ku, Tokyo
TEL 03-3542-2511
Email akawai@ncc.go.jp

Public contact
Name of contact person Kan Yonemori
Organization National cancer center hospital
Division name Breast and Medical Oncology
Address Tsukji 5-1-1 Chuo-ku Tokyo, Japan
TEL 03-3542-2511
Homepage URL
Email kyonemor@ncc.go.jp

Sponsor
Institute National cancer center hospital
Institute
Department

Funding Source
Organization None
Organization
Division
Category of Funding Organization Self funding
Nationality of Funding Organization

Other related organizations
Co-sponsor
Name of secondary funder(s)

Secondary IDs
Secondary IDs NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW

Institutions
Institutions

Other administrative information
Date of disclosure of the study information
2008 Year 12 Month 01 Day

Progress
Recruitment status Completed
Date of protocol fixation
2006 Year 03 Month 31 Day
Anticipated trial start date
2006 Year 07 Month 01 Day
Last follow-up date
2012 Year 07 Month 01 Day
Date of closure to data entry
Date trial data considered complete
Date analysis concluded

Related information
URL releasing protocol
Publication of results Unpublished
URL releasing results
Results
Other related information

Management information
Registered date
2008 Year 11 Month 26 Day
Last modified on
2018 Year 12 Month 13 Day


Link to view the page
URL(English) https://upload.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000001846